7:30 am Registration & Morning Coffee
8:20 am Chairperson’s Opening Remarks
Developing Conformation-Specific & Conformation Agnostic Therapeutics Against Misfolded & Oligomeric Proteins
8:30 am Small Molecule Inhibitors of a Common Conformational Morphology Identified in Intrinsically Disordered Proteins
- Marcia Taylor VP Research & Neurodegeneration Alliance Manager, Treventis
- Common Conformational Morphology (CCM) acts as an in silico crystal structure for IDPs
- Hit identification has been performed for alpha synuclein, amylin, amyloid beta, and tau
- Demonstrated dose dependent decrease in oligomeric species of amyloid beta and tau
9:00 am Amyloid Removal Therapy for Systemic Amyloidosis
- Aubin Michalon Principal Scientist, Neurimmune
• Generation of amyloid selective antibodies from human immune memory repertoires
• Lead selection and PoC studies with focus on assays with high translational value
• Modeling treatment response to support clinical trial design
9:30 am Antiviral Approaches Targeting Proteostasis are Safe, Effective and Do Not Elicit Drug Resistance
- Judith Frydman Professor, Stanford University
- Viruses are hyper-dependent on the host proteostasis machinery
- This provides an opportunity to develop broad spectrum antivirals that do not elicit drug resistance
10:00 am Exploring Conformational Changes and Multimerization of Proteins With a High-Throughput Conformation Biosensor
- Ulrich Rant CEO, Dynamic Biosensors
• Analysis of conformational changes in proteins induced by the binding of small molecules
• Real-time monitoring of multimerization and aggregation processes
• Discrimination of different ubiquitinylation states
• Description of high-throughput workflows with the heliX® biosensor
10:15 am Speed Networking & Morning Refreshments
11:20 am Examining the Effects of Sonication on Alpha Synuclein Pre-Formed Fibrils (PFFs)
- Ariel Louwrier President & CEO, StressMarq Biosciences Inc.
• Alpha synuclein and tau pre-formed fibrils (PFFs) are useful tools for modelling neurodegenerative diseases. Various types can be generated with different properties
• PFFs need to be sonicated prior to introducing them to cellular or animal models in order to generate disease pathology. This was originally thought to be because sonication reduces fibril length.
• Our data shows that solubility and fibril length both change with sonication. Increased solubility is more likely to account for the increased potency of oligomers and certain fibril types
11:30 am Rational Design of Conformation-Specific Antibodies Targeting Protein Aggregates
- Michele Vendruscolo Professor & CSO, Cambridge University Centre for Misfolding Diseases & Wren Therapeutics
• Discussing why protein oligomers are challenging targets for antibody discovery
• Presenting a method of antibody discovery for these targets
• Exploring how these antibodies can be used for diagnostics and therapeutics
12:00 pm Regulation of Proteostasis Networks in Aging & Disease
- Rick Morimoto Professor, Northwestern University
• Understanding how the proteostasis network is established in development to protect through reproduction and fails in adulthood and ageing
• Mapping out the course of events, including chaperone sequestration, that perpetuate protein aggregation and misfolding – what markers might be predictive of age-associated disease?
• Investigating the systemic consequence and communication of protein misfolding between tissues
Identifying Novel Therapeutics Using Innovative Drug Discovery Approaches
12:30 pm Engineered Chaperone Therapeutics: Transformative Therapeutics for Repairing Protein Misfolding of Conformational Diseases
- Akinori Hishiya Co-Founder & Chief Scientific Officer , SOLA Biosciences
- SOLA is a biotherapeutics company focusing on developing transformative therapies which enable the specific protein folding for disease-causing proteins
- SOL-01 diminishes aggregation of mutated huntingtin proteins without affecting wild-type huntingtin proteins, and SOL-02 suppresses misfolded alpha-synuclein proteins
- SOLA’s science team designs the technology for targeted protein folding. SOLA is looking for collaborators and partners to accelerate the therapeutic development
12:50 pm Networking Lunch
1:50 pm A Network Kinetics Drug Discovery Strategy for Targeting Protein Aggregation
- Johnny Habchi Head of Research, Wren Therapeutics
• Protein aggregation is a kinetics process, therefore kinetics readouts are needed
• Unravelling the mechanism of protein aggregation using chemical kinetics at a detailed microscopic level provides with an exceptional opportunity of a controlled intervention and consequently leads to a selective targeting of the toxic species
• The quantitative and predictive power of chemical kinetics allows for a systematic optimization of therapeutics molecules with desired properties
Optimizing Preclinical Models & Technologies for Robust Translation into the Clinic
2:20 pm Discovery & Clinical Translation of a Small-Molecule Inhibitor of α-Synuclein Toxicity
- Kenneth Rhodes CSO, Yumanity
• Using a yeast-to-human phenotypic screening platform we recently discovered that small molecule inhibitors of stearoyl-coA-desaturase (SCD) potently protect cells from α-synuclein toxicity
• Preclinical data confirmed that reduction of fatty-acid desaturation is correlated with protection, providing a translational pharmacodynamic marker that can be used in animals and human studies
• Focusing on the preclinical discovery and recent Phase Ia human clinical data from our lead SCD inhibitor, YTX-7739
2:50 pm Using Single Particle Detection Technologies to Quantify Pathological Tau in Extracellular Vesicles & Biofluids
- Matthew Townsend Global Director of Proteostasis, Alzheimer's Disease, AbbVie
• Outlining methods development
• Discussing the value of exosome capture in distinguishing AD from control
• Comparing CSF and plasma
3:20 pm Discussing ALZ-801 – A Phase 3 Ready Conformational Modifier with Disease Modifying for Alzheimer’s Disease
- John Hey CSO, Alzheon
- Presenting a small molecule modifier of protein misfolding through a novel “enveloping MOA”
- Discussing how these small molecule modifiers represent a promising new class of agents for neurodegenerative disease
Harnessing Cross-Learnings to Expand Therapeutic Portfolios into Novel Disease Indications
3:50 pm Cross-Learnings from Mechanisms of Action Underlying Protein Conformational Disorders
- Christopher Missling President & CEO, Anavex Life Sciences
- How to evaluate the safety and tolerability of novel protein misfolding therapeutics as assessed through clinical development
- How can the commonalities in underlying molecular pathology be used to inform the development of new treatment options for protein-misfolding diseases?
- How can you leverage a clinical developmental strategy to address a range of diseases caused by protein misfolding for which no approved disease-modifying treatments currently exist?
4:20 pm Afternoon Refreshments & Scientific Poster Session
After the formal presentations have finished, the learning and networking carries on.
The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on the latest advancements in therapeutic targeting of misfolded and oligomeric proteins.
4:50 pm Interactive Roundtable Discussions
Our breakout roundtables will allow you to have more intimate and open discussions on some of the hottest topics and key areas of debate. Drive your own learning, crowd-source ideas and get inspired. Immerse yourself in the following discussions:
- How to discover novel targets for next-generation therapeutics for protein conformational diseases?
- How to expand the applications of misfolded protein therapeutics beyond neurodegeneration?
- How to strategically accelerate misfolded protein research by leveraging the expertise, tools and resources at our disposal?